CA2387702A1 - The prv-1 gene and use thereof - Google Patents
The prv-1 gene and use thereof Download PDFInfo
- Publication number
- CA2387702A1 CA2387702A1 CA002387702A CA2387702A CA2387702A1 CA 2387702 A1 CA2387702 A1 CA 2387702A1 CA 002387702 A CA002387702 A CA 002387702A CA 2387702 A CA2387702 A CA 2387702A CA 2387702 A1 CA2387702 A1 CA 2387702A1
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- amino acids
- nucleotides
- prv
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Abstract
The invention relates to a necleotide sequence which codes for the PRV-1 protein and which essentially comprises the ID sequence N~.1. The invention also relates to a method for detecting this gene and the mRNA and the polypeptide that are coded for by this gene.
Description
The gene PRV-1 and its use Description The invention relates to a nucleotide sequence which encodes the PRV-1 gene, to recombinant DNA which contains this nucleotide sequence, to vectors which contain the recombinant DNA and to cells which are transformed with these vectors, and also to a PRV-1 polypeptide, to antibodies against this polypeptide, to a process for detecting the PRV-1 polypeptide and to drugs which comprise the PRV-1 polypeptide or antibodies which are directed against the PRV-1 _ polypeptide.
Polycythemia rubra vera (erythremia), also termed polycythemia vera or p. vera, is a malignant hematological disease in which there is an increased formation of erythroid, granulocytic and megakaryocytic cells. The disease is of clonal origin and arises as a result of the mutation of a single hematopoietic precursor cell. In Germany, the incidence of p. vera is from 4 to 6 per million inhabitants. If left untreated, the disease leads to death within 18 months. Treatment by means of blood-letting or chemotherapy extends the average survival time to more than 13 years.
P. vera is diagnosed by means of clinical criteria. The clinical picture includes headaches, pruritus, splenomegaly in two thirds of the patients, bleeding or thromboses, hypertension in a third of the patients, gout, which is brought about by an increase in the production of uric acid, and, in some cases, septic ulcers. The most important laboratory finding is an increase in the values for hemoglobin, hematocrit, erythrocyte count and total erythrocyte volume, and also a neutrophilic granulocytosis or thrombocytosis in many cases. Since, on the one hand, most of the criteria are rather diffuse and, on the other hand, not all the patients fulfill these criteria, it is _ 2 _ frequently difficult to distinguish p. vera from other myeloproliferative diseases, such as chronic granulocytic leukemia or essential thrombocytosis, and thereby confirm the diagnosis. To date, the molecular cause of p. vera is completely unknown. Since, however, p. vera takes a severe course if it is not treated, accurate diagnosis is important.
An object of the invention was therefore to find the molecular cause of polycythemia rubra vera and to create the possibility of diagnosing it.
This object was achieved by isolating a gene which is expressed specifically in association with p.
vera and not in healthy control individuals. This gene is designated the PRV-1 gene (polycythemia rubra vera).
A similar nucleotide sequence is disclosed in International application WO 98/50552.
One part of the subject matter of the invention therefore relates to a polynucleotide which encodes the PRV-1 gene and essentially comprises the sequence ID
No. 1. The polynucleotides of the present invention can be single-stranded or double-stranded DNA or RNA. If they are RNA, it is then clear to the skilled person that "U" nucleotides are present in place of "T"
nucleotides. "Polynucleotide" is understood as meaning nucleic acids which contain 15 or more nucleotides.
The nucleotide sequence according to the invention is depicted in figure 1. The invention therefore relates to a polynucleotide which corresponds to the sequence shown in figure 1 and also to a polynucleotide whose nucleotide sequence exhibits minor differences. Within the meaning of the present application, minor differences are understood as meaning those sequences in which a few, preferably not more than 50 and particularly preferably not more than 25, nucleotides can be exchanged, with, however, the function of the gene encoded by the nucleotide sequence being unaffected. The skilled person is familiar with the fact that a base triplet encoding an amino acid can be replaced with another triplet which encodes the same r amino acid. In addition to this, regions which are of less importance can be deleted and/or mutated to a minor extent. In a particular embodiment, the polynucleotide comprises nucleotides 36 to 1346 of sequence No. 1, that is the coding region of the PRV-1 gene. Other embodiments comprise nucleotides 36 to 1262 or 36 to 1238 of sequence No. 1. This region presumably encodes the active region of the PRV-1 polypeptide.
Finally, the polynucleotide of the invention can also comprise nucleotides 39 to 1346, 39 to 1262 or 39 to 1238 of sequence No. 1, such that the codon which encodes the starting methionine is not present. A
preferred embodiment is a polynucleotide which comprises nucleotides 99 to 1346, 99 to 1262 or 99 to 1238 of sequence No. 1. This results in the codons at the 5' end which encode the signal peptide of the PRV-1 polypeptide not being present.
The polynucleotide according to the invention can also be a fragment of the PRV-1 gene. As a rule, the fragment possesses more than 100 nucleotides, preferably, however, more than 300 nucleotides. The fragments can also be used as primers or as probes, in particular for PCR; in this case, the fragments can be truncated to fit the purpose. Usually, primers have a length of between 10 and 30 nucleotides and probes have a length of between 15 and 50 nucleotides.
The PRV-1 gene is an endogenous gene whose expression in healthy individuals is, however, restricted to only a few organs. Normally, it is expressed in the main in the hematopoietic organs, i.e.
in bone marrow and fetal liver, and weakly expressed in the spleen, but not expressed in heart, muscle, pancreas or kidney. In patients who are suffering from p. vera, this gene is very strongly overexpressed in the hematopoietic cells, in particular.
The PRV-1 gene encodes a protein which exhibits the protein sequence shown in Figure 2. The signal peptide, which is present in the protein sequence of all surface molecules and normally removed when the protein is processed, is divided off by a hyphen. The protein has the sequence ID No. 2. Another aspect of the invention is consequently an essentially pure polypeptide having the sequence No. 2 or a polypeptide having the sequence No. 2 but lacking the signal peptide (i.e. amino acids 22 to 437 of sequence No. 2).
Other embodiments encompass amino acids 1 to 409, 22 to 409, 1 to 401 or 22 to 401 of sequence No. 2 (what is probably the active region of the protein).
With regard to biological activity, the polypeptide according to the invention is preferably glycosylated; it is most preferably N-glycosylated. It can then be glycosylated at at least one of the amino acids Asn-46, Asn-189 and Asn-382 of the PRV-1 polypeptide (the amino acid numbers refer to the sequence No. 2). The invention also encompasses fragments of the polypeptides according to the invention which are N-glycosylated. The fragments are at least 50 amino acids in length, preferably at least 100 amino acids and most preferably at least 150 amino acids. In another embodiment, a polypeptide can be O-glycosylated.
It is clear to the skilled person that particular amino acids can be replaced with other amino acids without impairing the biological activity of the protein. Such modified forms of the polypeptides according to the invention are also part of the subject matter of the invention (variants). The amino acid replacements are those which do not have a negative effect on the biological activity of the protein. The skilled person can make use of well known rules for selecting the replacements.
Depending on the method of preparation, the PRV-1 polypeptide can, for example, possess a glycosyl phosphatidylinositol anchor. This is then bonded to the amino acids which correspond to amino acids 407 to 409 in sequence ID No. 2. A GPI anchor is used to anchor a protein by means of a lipid on the outside of the cell membrane. However, for reasons which have not so far ~ - 5 -been conclusively elucidated, it is frequently observed that GPI-linked proteins are also released into the medium. This is referred to as "shedding" . To date, it has not been clarified whether this is a specific process, i.e. such proteins are cleaved from the membrane by enzymes in a controlled manner, or whether it represents a non-specific loss of the anchor. It is consequently very probable that PRV-1 is to be found both on the cell membrane and extracellularly. The secreted form, which is not membrane-bound, is probably more important for the effect of the polypeptide as a growth factor and growth inhibitor since, as a growth factor, this form is able to diffuse and reach other cells.
It is clear to the skilled person that he can influence the attachment of the protein to the cell membrane by manipulating these C-terminal amino acids.
This particularly concerns the preparation of defined DNA constructs which are intended for expressing the PRV-1 polypeptide or fragments of this polypeptide. The codons which encode these amino acids can be mutated or deleted.
The gene encodes a surface receptor of the uPAR/Ly6 family. This receptor family can transduce mitogenic signals, i.e. signals which stimulate cell division. It is therefore assumed that overexpression of the PRV-1 gene, inter alia on the bone marrow cells of p. vera patients, contributes to hyperproliferation of these cells.
It has been found that PRV-1 is not expressed on granulocytes in healthy individuals or in patients suffering from other myeloproliferative diseases, e.g.
suffering from chronic granulocytic leukemia, acute granulocytic leukemia, essential thrombocytosis or secondary erythrocytosis.
In order to be able to use the polypeptide encoded by the PRV-1 gene for analyses and detection methods, it is expediently generated from recombinant DNA, with the recombinant DNA preferably comprising the -nucleotide sequence ID No. 1 or at least the coding region of the PRV-1 gene, that is nucleotides 36 to 1346 of sequence ID No. l, or else at least nucleotides 39 to 1262 or 39 to 1238, functionally linked to a promoter. However, the recombinant DNA can also comprise only a fragment of sequence No. 1.
The invention furthermore relates to a vector which contains the recombinant DNA for the PRV-1 polypeptide, or a fragment thereof, and to a host cell which is transfected or transformed with this vector.
The host cells may be prokaryotic, for example bacteria such as E. coli. However, the polypeptides which are expressed are then not glycosylated. Preference is therefore given to eukaryotic host cells, which are able to glycosylate the expressed protein post-translationally and modify it in other ways. Examples of eukaryotic host cells are insect cells, such as Sf9 cells, for expression following infection with recombinant baculoviruses, and mammalian cells, such as 293 cells, COS cells, CHO cells and HeLa cells. These examples are not exhaustive. It is also possible to use yeast cells as host cells. It is clear to the skilled person that the glycosylation pattern can differ depending on the host cell. The biological activity of the expression product can therefore also vary.
Particular preference is given to host cells which glycosylate the expression product in such a way that the biological activity of the protein is retained.
Another aspect of the invention is a process for preparing a polypeptide according to the invention.
In this process, a DNA encoding the polypeptide according to the invention is caused to be expressed in a host cell. The culture medium or the cells is/are employed for the subsequent isolation of the polypeptide depending on whether the expressed polypeptide is secreted by the host cell into the culture medium or remains in the cell. After that, the polypeptide according to the invention is concentrated and/or purified using methods which are known in the state of the art, for example chromatographic methods.
Methods for purifying proteins are described, for example, in Scopes, R., Protein Purification:
Principles and Practice (3rd edition), Springer Verlag (1994). In one particular embodiment, the process according to the invention encompasses the step in which glycosylated polypeptide is concentrated and/or purified. This step can take place either before the polypeptide according to the invention has been essentially purified or after it has already been essentially purified. In the latter case, the glycosylated moiety of the purified polypeptide is then separated off and isolated. In the most preferred embodiment of the process, N-glycosylated polypeptide is specifically isolated. In another embodiment of the process, polypeptide is isolated which is glycosylated at at least one of the amino acids Asn-46, Asn-189 and Asn-382 of sequence No. 2.
The PRV-1 polypeptide which is isolated from granulocytes or produced recombinantly can be employed both for diagnosing polycythemia vera and for treating the disease.
One therapeutic possibility is that of "antisense therapy". This method employs an "antisense"
RNA molecule, that is an RNA which is complementary to the PRV RNA. Since the PRV-1 RNA has the sequence 5'-AAAAGCAGAAAGAGATTACCAGCC-3' (seq. ID No. 3) at its beginning, the requisite antisense RNA directed against this sequence would possess the following nucleotide sequence: 5'-GGCTGGTAATCTCTTTCTGCTTTT-3' (seq. ID No.
4). This antisense RNA is incorporated into a vector and introduced into the p. vera cells. This RNA is introduced, for example, by means of transfection, with the vector used for the transfection preferably being configured such that it is introduced specifically into the p. vera cells. Expression of the antisense RNA
results in it no longer being possible for the PRV-1 mRNA to be translated into a polypeptide. Cells which a have been treated in this way do not then form any PRV-1 protein.
The invention therefore also relates to a process for detecting p. vera which is characterized in that the PRV-1 polypeptide, or an epitope thereof, is detected and the extent of the expression is determined.
Overexpression of this receptor on mature cells outside of the bone marrow, e.g. on granulocytes, is a strong indication of the presence of the disease p.
vera. This overexpression is expediently detected by means of an immunoassay using antibodies which are directed against the PRV-1 receptor. Suitable test methods are the known immunoassay variants which make use of PRV-1 polypeptide-specific antibodies together with other labeled antibodies which can be immobilized or in solution. The labeling can be effected in a manner known per se, for example using radioactive isotopes, by means of fluorescence or luminescence, using enzymes, by means of color-forming reactions or using other groups which are suitable for the determination. These variants are known to the skilled person and do not require any more detailed explanation here. According to the invention, ELISA tests are particularly preferred.
The antibodies which are required for specifically detecting the PRV-1 receptor can likewise be prepared in a manner which is known per se. Both monoclonal and polyclonal antibodies are suitable, with preference being given to using monoclonal antibodies.
Peptides which are derived from the protein can also be used for preparing antibodies. Within the context of the present invention, success was achieved using the peptides having the sequences:
a) KVSDLPRQWTPKN (amino acids 34 to 46) (seq. ID No.
5~, and _ g _ b) SAREKRDVQPPASQH (amino acids 391 to 405) [seq. ID
No. 6] .
The polyclonal antibodies are normally produced by immunizing a suitable host (rabbit) with the PRV-1 polypeptide, where appropriate bound to an immunological support (adjuvant), and eliciting an immune response. Monoclonal antibodies can be generated in a manner known per se using the hybridoma technique.
The antibodies can be purified by means of affinity purification. The preparation and purification of antibodies are described, for example, in "Antibodies:
A Laboratory Manual" by Harlow and Lane, Cold Spring Harbor Laboratory Press.
Furthermore, such polyclonal or monoclonal antibodies which are directed against PRV-1 can also be used for treating the disease.
In another embodiment, the PRV-1 receptor can be detected using an RT-PCR method. For this, RNA is first of all isolated from the PRV-1-overexpressing cells, which are as a rule granulocytes. A reverse transcription is then performed in a manner known per se using an RT primer. The RT primer is preferably a primer which has the following nucleotide sequence (SEQ
ID No. 7):
ATTAGGTTATGAGGTCAGAGGGAGGTT.
In this way, the specific PRV-1 RNA is transformed into DNA. This DNA is then amplified in a PCR reaction in a manner known per se. The following two primers are preferably employed for the amplification cycles:
As the sense primer (SEQ ID No. 8) GCAGAAAGAGATTACCAGCCACAGACGG.
As the antisense primer (SEQ ID No. 9) GAATCGTGGGGGTAATAGAGTTAGCAGG.
The skilled person is readily able to use the disclosed sequence to find other primers which are also suitable.
Since the RNA is used as the starting material for this method, the PCR signal is only positive when the PRV-1 gene is also expressed. As explained above, this is only the case when the patient is suffering from p. vera. PRV is not expressed in granulocytes of healthy patients. Consequently, the absence of any RT-PCR signal indicates that no p. vera is present. The quantification in the RT-PCR method is preferably effected using the TaqMan~ technology. This quantification requires a probe in addition to primers.
The preferred sequence of the probe is 5'-TTCTTGTTGAACCACACCAGACAAATCGG-3' (SEQ ID N0:10~.
Quantitative RT-PCR for detecting the PRV-1 transcript is therefore also part of the subject matter of this invention.
In another alternative, it is also possible to use a blotting method, preferably a Northern Blot, for diagnosing p. vera. For such a method, the RNA is isolated from granulocytes and then examined for the expression of PRV-1 using a blotting method, for example Northern blotting. The cDNA sequence of SEQ ID
No. 1, or a segment of the sequence, can be used as the probe. Hybridization then only occurs if the granulocytes are derived from a patient suffering from p. vera since only then is there any expression on the granulocytes. The absence of hybridization indicates that the individual from whom the granulocytes are derived does not have p. vera.
It is also possible to use a fragment of the gene for the Northern blot hybridization. Such a fragment is normally more than 100 bases in length, preferably more than 300 bases in length.
Alternatively, various different fragments of the gene, ' - 11 -which can be used as probes in the Northern blot, can be prepared by digesting the gene with restriction endonucleases. If the fragments are derived from the cDNA, they are then present as double strands which have to be separated into the single strands for the hybridization. Suitable examples are the Bam HI-PstI
fragment from base pair 420 to base pair 831, or the PstI-PstI fragment from base pair 831 to base pair 1900.
PRV-1 mRNA, and consequently the expression of PRV-1, can also be detected by first of all reverse-transcribing the mRNA in an RT-PCR reaction and then amplifying the cDNA; the amplified DNA is then detected with a probe in a hybridization method.
In the case of a positive diagnosis, the disease has to be treated since it otherwise leads to death within a relatively short period of time. For this treatment, it is possible to use specific antibodies which are directed against PRV-1 and to which cytotoxic components can be bonded, where appropriate.
The invention therefore furthermore relates to a drug which, in addition to the customary excipients, comprises antibodies which are directed against the PRV-1 receptor.
Since the PRV-1 receptor is overexpressed in p.
vera, many antibodies are bound on the surface of the affected granulocytes when they come into contact with the anti-PRV-1 antibody. The binding of many antibodies to these cells stimulates the immunological cells to destroy these granulocytes. In this way, it is possible to eliminate the p. vera cells specifically.
Surprisingly, it has also been found that the PRV-1 polypeptide exhibits haematopoietic activity. The PRV-1 polypeptide is able to stimulate certain hematopoietic precursor cells to form erythroid colonies. It is particularly the N-glycosylated PRV-1 polypeptides which display this function. The polypeptides according to the invention which are preferred are therefore the N-glycosylated PRV-1 polypeptides, and fragments thereof, which display the growth factor activity.
Another aspect of the invention is therefore a drug which, in addition to a pharmaceutically tolerated excipient, comprises the PRV-1 polypeptide or a biologically active fragment thereof. The PRV-1 polypeptide is preferably glycosylated PRV-1 polypeptide and, even more preferably, N-glycosylated PRV-1 polypeptide or a biologically active fragment thereof. The invention also relates to drugs which comprise at least one polynucleotide according to the invention.
The present invention furthermore relates to the use of PRV-1 polypeptide, or a biologically active fragment thereof or a biologically active variant thereof, as a growth factor in vivo and ex vivo. The PRV-1 polypeptide, or a biologically active fragment thereof or a biologically active variant thereof, can be used for treating all pancytopenias and pancytopathies in the bone marrow and in the circulation (change in the cellular constituents of the peripheral blood and bone marrow). The polypeptides of the present invention can, for example, be used for treating anemias in the case of kidney failure, chemotherapy or whole body radiation, for treating neutropenias and thrombocytopenias during chemotherapy or whole body radiation, for the ex-vivo treatment of peripheral or bone marrow stem cells for expansion (multiplication) and retransfusion into the patients, and for treating sepsis, systemic inflammatory response syndrome (SIRS) or regional inflammatory reactions. The polypeptides of the present invention, or drugs which comprise them, can be administered in a wide variety of ways. The forms of administration comprise intravenous, intramuscular, subcutaneous, intraperitoneal, oral, transdermal and transmucosal administration.
The polynucleotides according to the invention can also be used for treating pancytopenias and pancytopathies. In this case, the aim is to express a PRV-1 polypeptide, or a functional fragment thereof, in cells of the affected patient. Gene therapy methods are first and foremost used in this connection. Cells can be isolated from the patient and transfected with a polynucleotide according to the invention (ex-vivo manipulation), after which they are then returned to the patient. It is also possible to conceive of methods in which the polynucleotides according to the invention gain access into the target cells by means of viral transfer. Expression of the inserted nucleic acids then leads to haematopoietic activity.
Surprisingly, it was also found that, at higher concentration, the PRV-1 polypeptide has an inhibitory effect on the growth of cells. Thus, it was observed, for example, that adding an increased quantity of PRV-1 protein virtually completely stops the formation of erythroid and granulocytic/monocytic colonies. This effect resembles the action of Interferon-a, which is used, inter alia, therapeutically in chronic myeloid leukemia (CML) and in p. vera. An endogenous inhibitory substance possesses great advantages as compared with a chemical cytostatic agent, such as hydroxyurea, which was used when Interferon-a was not yet available and is to some extent still used. A disadvantage of Interferon-a is that this active compound has very severe side effects. The patients feel as if they were suffering from a serious influenza. The present invention makes available a hematopoiesis-inhibiting substance, with the inhibitory activity being concentration-dependent.
Another aspect of the invention is therefore the use of a PRV-1 polypeptide, as described in this application, for inhibiting the growth of cells, in particular its use as a cytostatic agent. Preference is given to the polypeptide being used for inhibiting the growth of hematopoietic cells. The invention also relates to the use of a polypeptide according to the invention for producing a drug for treating proliferative diseases. These diseases are, in particular, the myeloproliferative diseases, p. vera, essential thrombocythernia, myelofibrosis, CML and also all leukemias and lymphomas and also solid tumors.
Another aspect of the invention is the use of a polynucleotide, as described in this application, of a biologically active fragment or of a biologically active variant thereof, for inhibiting the growth of cells. The polynucleotide can be incorporated into a suitable vector and transfected into suitable target cells. After the PRV-1 polypeptide, or a biologically active fragment thereof, or a biologically active variant thereof, has been expressed in an appropriate concentration, the growth-inhibiting effect comes into operation. In the same way, the polynucleotide can be incorporated into a viral vector, after which appropriate target cells are infected virally, leading to PRV-1 being expressed. The invention also relates to the use of a polynucleotide of this application for producing a drug for treating proliferative diseases, such as the myeloproliferative diseases, p. vera, essential thrombocythemia, myelofibrosis, CML and also all leukemias and lymphomas and also solid tumors.
The invention also relates to kits for detecting either polycythemia vera or disturbances of the hematopoietic system. These kits comprise a polynucleotide according to the invention and/or a polypeptide according to the invention and/or one or more antibodies according to the invention. In addition to this, the kit can also comprise a container or compositions which are suitable for implementing detection reactions. Examples of such compositions are buffer solutions, reagents for blocking membranes, hybridization solutions, secondary antibodies, substrate solutions for detection reactions, etc. The kit is preferably used for implementing PCR reactions, RT-PCR, Northern blots, Southern blots, Western blots and ELISA, RIA or similar reactions.
The following examples are given in explanation.
Example 1 Characterizing the PRV gene The following experiments were carried out in order to characterize the gene:
- the following protocol was used to isolate granulocytes from stored blood or from blood obtained by bleeding p. vera patients:
- an equal volume of 3~ dextran solution in 0.9~
NaCl was added to the blood and the mixture was left to stand at room temperature (RT) for 20 minutes.
- The mixture separated into two phases. The upper, light-colored phase was removed and centrifuged for 10 minutes at 1800 g and at RT.
- The supernatant was discarded and the cell pellet was resuspended in the same volume of 0.9~ NaCl.
- In each case 35 ml of the cells in NaCl were layered on 15 ml of Ficoll-Hypaque.
- The cells on the Ficoll-Hypaque were then centrifuged for 60 minutes at 1800 g and at RT without using the brake.
- A cell pellet and two layers with an interphase were formed.
- The layers and interphase were aspirated off and the cell pellet was resuspended for 30 seconds in 10 ml of ice-cold 0.2~ NaCl, and 10 ml of ice-cold 1.6g NaCl were added immediately after 30 seconds.
- The cells were centrifuged down for 10 minutes at 1800 g and at RT.
- They were then washed once in 10 ml of PBS and centrifuged down.
- The cell pellet contained 95-99~-pure granulocytes.
- RNA was isolated from these cells using standard methods.
- 10 mg of this RNA were examined for the expression of PRV-1 in a Northern blot. The entire cDNA
sequence shown in SEQ ID No. 1 was used as a probe.
This experiment was performed on 39 p. vera patients and 29 control samples of stored blood. The PRV-1 probe was found to hybridize strongly in the case of the p. vera patients. No hybridization was observed in healthy control samples.
Example 2 PRV-1 possesses growth factor activity Embryos were removed from a pregnant mouse 13.5 days after fertilization. The fetal livers were removed. The cells contained in them were stained using antibodies and enriched for particular cells, and depleted for other cell types, by means of column chromatography. This results in a cell mixture which is enriched for certain hematopoietic precursor cells (colony forming units-erythroid, CFU-E). Thus, while in all approximately 2~ of the fetal liver consists of CFU-E, 30-40~ of the enriched cells consist of CFU-E.
These CFU-Es were transfected using a retrovirus. To do this, a packaging cell line, designated 293-T, was itself transfected 48 hours previously. 293-T cells are an established human embryonic kidney cell line. 293-T cells are stably transfected with several genes from a retrovirus. If these 293-T cells are now transfected with two plasmids, termed pOS and pKAT, the 293-T cells then produce ~a retrovirus which is able to infect murine fetal liver cells. If the 293-T cells are transfected with an empty pOS vector and pKAT, a wild-type retrovirus, which only expresses retroviral proteins, is then produced. On the other hand, cloning a human gene, e.g. PRV-1, into the pOS vector results in the production of a retrovirus which expresses this protein _ 1~ -when it has infected cells. The 293-T cells secrete the retrovirus into the cell culture medium.
After two days, the cell culture medium from the transfected 293-T cells which contains the retrovirus is harvested and filtered once through a 0.45 um filter. In order to transfect the fetal liver cells, these latter cells are mixed with the filtered cell culture medium, which contains the retrovirus, and centrifuged for 2 hours at 1800 rpm and 20°C in the added presence of Polybren. The transfected fetal liver cells were then cultured in a medium (Methocult, from Cell Systems) which contains, in addition to the usual salts and amino acids, fetal calf serum, 0.0001-0.4 IU
of erythropoeitin (EPO)/ml and methyl cellulose (0.8~).
The CFU-Es require EPO in order to form hematopoietic colonies. The methyl cellulose solidifies the medium in the form of a jelly, thereby fixing individual cells in this jelly so that, in contrast to being in a liquid medium, they cannot move. It is therefore possible to observe whether a hematopoietic colony is or is not formed from a single cell. CFU-Es form erythroid colonies, that is colonies which contain red blood cells and their precursor cells.
After three days, a count is taken of the number of hematopoietic colonies which have developed.
Various mixtures are compared. The mixtures were not all examined in each experiment; mixtures 1-3 are very similar controls and each of them can be compared individually with mixture 4.
Mixture 1: Cells which were not transfected with a retrovirus;
Mixture 2: Cells which were transfected with an empty pOS vector;
Mixture 3: Cells which were transfected with a "green fluorescent protein" (GFP), a protein which is not hematopoietically active.
Mixture 4: Cells which were transfected with pOS-PRV-1 (vector + gene according to the invention).
Table 1: The table lists the results obtained from three experiments which were performed as described. The figures in each case indicate the number of colonies.
Mixture 1 Mixture 2 Mixture Mixture 4 un- empty vector GFP PRV-1 transfected (pOS) (pOS-GFP) (pOS-PRV-1) Experiment 116 156 80 326 Experiment 271 273 410 Experiment 120 131 291 The experiments demonstrate that CFU-Es which were transfected with PRV-1 form very many more colonies (up to three times as many) than do the various control CFU-Es. This result indicates that PRV-1 is a growth factor for CFU-E.
Example 3 Solubility of the PRV-1 growth factor A further experiment was carried out in order to investigate whether PRV-1 is a soluble growth factor or whether cell-cell contact is required. It is not only a retrovirus which is produced by the packaging cell line 293-T after it has been transfected with the pOS and pKAT vectors. In addition, the 293-T cells also synthesize the protein encoded by the gene cloned in pOS, i.e. PRV-1 in the present case. If the gene product is a soluble protein, it is secreted into the medium which surrounds the packaging cell line 293-T.
If the 293-T cells are transfected only with the pOS
vector, without pKAT, no retroviruses are then formed.
The cell culture medium then only contains the soluble protein produced by the cells. Medium which is derived from pOS-PRV-1-transfected cells, and which does not contain any retrovirus, is mixed with CFU-Es and the whole is plated out in the methyl cellulose medium; the resulting colonies are then counted.
The following results were obtained:
Table 2: Solubility of PRV-1. The figures in each case indicate the number of colonies.
Mixture 1 Mixture 2 Mixture Mixture 4 un- empty vector GFP PRV-1 transfected (pOS) (pOS-GFP) (pOS-PRV-1) Experiment 137 187 557 In this experiment, too, CFU-Es which were treated with PRV-1-containing medium formed very many more hematopoietic colonies than did control cells. It can be concluded from this result that PRV-1 is a soluble growth factor.
Example 4 PRV-1 also has an inhibitory, cytostatic effect.
The experiments were carried out on peripheral blood cells. Since a small number of precursor cells are also circulating in the peripheral blood in healthy individuals, it is possible to culture hematopoietic colonies from peripheral blood cells in a suitable medium (methyl cellulose). 40 ml of peripheral venous blood were withdrawn from a healthy donor (while initially introducing heparin or EDTA as an anticoagulant). 15 ml of Ficoll/Hypaque were added to the blood and the mixture was centrifuged at 1 600 rpm for 40 minutes without braking. This results in the production of a density gradient which fractionates the blood into its cellular constituents. After the centrifugation, what are termed the mononuclear cells, which also include the stem cells, are to be found at the interphase between serum and Ficoll. This interphase was removed and washed in PBS (isotonic salt solution). This yields purified mononuclear cells, approximately 0.1~ of which are hematopoietic stem cells.
The mononuclear cells were taken up in a particularly rich medium (IMDM) which contained an added concentration of 3$ FCS (fetal calf serum) . This 3~ FCS/IMDM subsequently contained the modifications, i.e. PRV-1 was or was not added to it.
The mononuclear cells in IMDM were added, at a density of 7 x 105 cells/ml, to a commercially available medium supplied by Stem Cell Technologies (Methocult), which contained IMDM and 30$ FCS, 1~ BSA (bovine serum albumin), mercaptoethanol, 2 mM L-glutamine, 3 IU EPO
(erythropoietin)/ml and 1.0~ methyl cellulose. The cells grew for 14 days in this medium. The few stem cells which are present in this mixture are able to develop into hematopoietic colonies. Usually, between 100 and 200 hematopoietic colonies develop for every 7 x 105 cells employed.
A cell line which expresses a very high quantity of PRV-1 was also constructed. The PRV-1 which is produced by these cells is altered such that it no longer possesses a lipid anchor. The expression product consists of the amino acids 1-401 of the sequence SEQ ID No:2; the amino acids 402-437 are therefore missing. This altered PRV-1 is therefore not, like wild-type PRV-1, incorporated into the cell membrane by means of a lipid anchor, but is instead completely secreted from the cells. As in example 3, the cell line consisted of 293 cells which do not produce any retrovirus but which express protein (PRV-1).
For the hematopoietic colony assays, the mononuclear blood cells were now taken up either in IMDM medium, which had been incubated for 48 hours with untransfected cells (293), or in medium which had been incubated for 48 hours with cells which were expressing the altered PRV-1 (293-GPI-less-PRV-1). The ability of these cells to form hematopoietic colonies was then investigated. The number of erythroid (red) and myeloid (white) blood cell colonies was determined after 14 days. The experiment was repeated three times and also carried out on different days and using different blood donors. Duplicates were also evaluated within the experiment. The following results were obtained:
Experiment 1 Cell Donor 1 Donor 2 supernatant Red White Red White colonies colonies colonies colonies 293-GPI-less- 7/3 0/0 31/19 0/0 Experiment 2 Cell Donor 1 Donor 2 supernatant Red White Red White colonies colonies colonies colonies 293-GPI-less- 0/0 0/0 0/0 0/0 Experiment 3 Cell Donor 1 Donor 2 supernatant Red White Red White colonies colonies colonies colonies s 293-GPI-less- 4/3 0/6 0/1 3/0 It can be concluded from this data that a higher dose of PRV-1 than that used in example 3 possesses a cytostatic effect.
Example 5 The growth factor PRV-1 is N-glycosylated Granulocytes were isolated from a patient suffering from p. vera, and protein extracts were prepared from these cells using a standard protocol.
These protein extracts were treated in accordance with the protocol for the "N-Glycosidase F Deglycosylation Kit" supplied by Boehringer Mannheim. In detail, this means that a "denaturation buffer" was added to the protein extracts and the mixtures were heated at 95°C
for 3 minutes, after which they were treated either with "reaction buffer" or with "reaction buffer" plus N-glycosidase. Each mixture was incubated overnight at 37°C and the proteins were analyzed on a PAGE gel electrophoresis followed by a Western blot. The PRV-1 protein was detected with an antibody directed against a protein having the amino acid sequence ID No. 5. The results show that while PRV-1 protein purified from granulocytes is 60-65 kDa in size, it is only 40 kDa in size after having been digested with N-glycosidase.
This clearly proves that PRV-1 is glycosylated on asparagine residues (asparagine = N).
SEQUEPICE LISTII~IG
<110> Universitatsklinikum Freiburg <120> THE PRV-1 GENE AiID USE THEREOF
<130> E980930 <140> PCT/EP00/09594 <141> 2000-09-29 <150> DE 199 47 010.3 <151> 1999-09-30 <160> 10 <170> PADAT Sequenzmodul, Version I.0 <210> 1 <211> 1600 <212> DNA
<213> homo Sapiens <220>
<223>
<400> 1 aaaagcagaaagagattaccagccacagacgggtcatgagcgcggtattactgctggcc= 60 tcctggggttcatcctcccactgccaggagtgcaggcgctgctctgccagtttgggacag 120 ttcagcatgtgtggaaggtgtccgacctgccccggcaatggacccctaagaa~~accagct180 gcgacagcggcttggggtgccaggacacgttgatgctcattgagagcggaccccaagtga 240 gcctggtgctctccaagggctgcacggaggccaaggaccaggagccccgcgtcactgagc 300 accggatgggccccggcctctccctgatctcctacaccttcgtgtgccgccaggaggact 360 tctgcaacaacctcgttaactccctcccgctttgggccccacagcccccagcagacccaa 420 gatccttgaggtgcccagtctgcttgtctatggaaggctgtctggaggggacaacagaag 480 agatctgccccaaggggaccacacactgttatgatggcctcctcaggctcaggggaggag 540 gcatcttctccaatctgagagtccagggatgcatgccccagccaggttgcaacctgctca 600 atgggacacaggaaattgggcccgtgggtatgactgagaactgcaataggaaagatttt= 660 tgacctgtcatcgggggaccaccattatgacacacggaaacttggctcaagaacccactg 720 attggaccacatcgaataccgagatgtgcgaggtggggcaggtgtgtcaggagacgctg= 780 tgctcatagatgtaggactcacatcaaccctggtggggacaaaaggctgcagcactgttg 840 gggctcaaaattcccagaagaccaccatccactcagcccctcctggggtgcttgtggcct 900 cctatacccacttctgctcctcggacctgtgcaatagtgccagcagcagcagcgttctgc 960 tgaactccctccctcctcaagctgcccctgtcccaggagaccggcagtgtcctacctgtg 1020 tgcagccccttggaacctgttcaagtggctccccccgaatgacctgccccaggggcgcca 100 ctcattgttatgatgggtacattcatctctcaggaggtgggctgtccaccaaaatgagca 1140 ttcagggctgcgtggcccaaccttccagcttcttgttgaaccacaccagacaaatcggg~ 1200 tcttctctgcgcgtgagaagcgtgatgtgcagcctcctgcctctcagcatgagggaggtg 1260 gggctgagggcctggagtctctcacttggggggtggggctggcactggccccagcgctgt 1320 ggtggggagtggtttgcccttcctgctaactctattacccccacgattcttcaccgctgc 1380 tgaccacccacactcaacctccctctgacctcataacctaatggccttggacaccagatt 1~d0 ctttcccattctgtccatgaatcatcttccccacacacaatcattcatatctactcacct 1500 aacagcaacactggggagagcctggagcatccggacttgccctatgggagaggggacgct 1560 ggaggagtggctgcatgtatctgataatacagaccctgtc 1600 <210>
<211>
<212>
PRT
<213> Sapiens homo <400> 2 Met Ser Ala Val Leu Leu Leu Ala Leu Leu Gly Phe Ile Leu Pro Leu Pro Gly Val Gln Ala Leu Leu Cys Gln Phe Gly Thr Val Gln His 'Jal Trp Lys Val Ser Asp Leu Pro Arg Gln Trp Thr Pro Lys Asn Thr Ser Cys Asp Ser Gly Leu Gly Cys Gln Asp Thr Leu Met Leu Ile Glu Ser Gly Pro Gln Val Ser Leu Val Leu Ser Lys Gly Cys Thr Glu Ala Lys Asp Gln Glu Pro Arg Val Thr Glu His Arg Met Gly Pro Gly Leu Ser Leu Ile Ser Tyr Thr Phe Val Cys Arg Gln Glu Asp Phe Cys Asn Asn Leu Val Asn Ser Leu Pro Leu Trp Ala Pro Gln Pro Pro Ala Asp Pro Gly Ser Leu Arg Cys Pro Val Cys Leu Ser Met Glu Gly Cys Lsu Glu Gly Thr Thr Glu Glu Ile Cys Pro Lys Gly Thr Thr His Cys Tyr Asp Gly Leu Leu Arg Leu Arg Gly Gly Gly Ile Phe Ser Asn Leu Arg Val Gln Gly Cys Met Pro Gln Pro Gl,v Cys Asn Leu Leu Asn Gly Thr Gln Glu Ile Gly Pro Val Gly Met Thr Glu Asn Cys Asn Arg Lys Asp Phe Leu Thr Cys His Arg Gly Thr Thr Ile hfet Thr His Gly Asn Leu Ala Gln Glu Pro Thr Asp Trp Thr Thr Ser Asn Thr Glu Met Cys Glu Val Gly Gln Val Cys Gln Glu Thr Leu Leu Leu Ile Asp Val Gly L?u Thr Ser Thr Leu Val Gly Thr Lys Gly Cys Ser Thr Val Gly Ala Gln Asn Ser Gln Lys Thr Thr Ile His Ser Ala Pro Pro Gly Val Leu Val Ala Ser Tyr Thr His Phe Cys Ser Ser Asp Leu Cys Asn Ser Ala Ser Ser Ser Ser Val Leu Leu Asn Ser Leu Pro Pro Gln Ala Ala Pro ~.'al Pro Gly Asp Arg Gln Cys Pro Thr Cys Val Gln Pro Leu Gly Thr Cls Ser Ser Gly Ser Pro Arg Met Thr Cys Pro Arg Gly Ala Thr His Cls Tyr Asp Gly Tyr Ile His Leu Ser G1,; Gly Gly Leu Ser Thr Lys ffet Ser Ile Gln Gly Cys Val Ala Gln Pro Ser Ser Phe Leu Leu Asn His Thr Arg Gln Ile Gly Ile Phe Ser Ala Arg Glu Lys Arg Asp Val Gln Pro Pro Ala Ser Gln His Glu Gly Gly Gly Ala Glu Gly Leu Glu Ser Leu Thr Trp Gly Val Gly Leu Ala Leu Ala Pro Ala Leu Trp Trp Gljr Val Val Cys Pro Ser Cys <210> 3 <211> 24 <212> RNA
<213> Artificial Sequence <220>
<223> 5'-end of PRV-1-sequence <400> 3 aaaagcagaa agagattacc agcc 24 <210> 4 <211> 24 <212> RNA
<213> Artificial Sequence <220>
<223> Antisense-Molecule <400> 4 ggctggtaat ctctttctgc tttt 2:~
<210> 5 <211> 13 <212> PRT
<213> Artificial Sequence <220>
<223> amino acids 34-46 of PRV-1 <900> 5 Lys Val Ser Asp Leu Pro Arg Gln Trp Thr Pro Lys Asn <210> 6 <211> 15 <212> PRT
<213> Artificial Sequence <220>
<223> amino acids 391-405 of PRV-1 <400> 6 Ser Ala Arg Glu Lys Arg Asp Val Gln Pro Pro Ala Ser Gln His <210> 7 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> RT-Primer <400> 7 attaggttat gaggtcagag ggaggtt 27 <210> a <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> sense-Primer <400> 8 gcagaaagag attaccagcc acagacgg 2~
<210> 9 <211> 28 <212> DDTA
<213> Artificial Sequence <220>
<223> antisense-Primer <400> 9 gaatcgtggg ggtaatagag ttagcagg <210> 10 <211> 29 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 10 ttcttgttga accacaccag acaaatcgg 29
Polycythemia rubra vera (erythremia), also termed polycythemia vera or p. vera, is a malignant hematological disease in which there is an increased formation of erythroid, granulocytic and megakaryocytic cells. The disease is of clonal origin and arises as a result of the mutation of a single hematopoietic precursor cell. In Germany, the incidence of p. vera is from 4 to 6 per million inhabitants. If left untreated, the disease leads to death within 18 months. Treatment by means of blood-letting or chemotherapy extends the average survival time to more than 13 years.
P. vera is diagnosed by means of clinical criteria. The clinical picture includes headaches, pruritus, splenomegaly in two thirds of the patients, bleeding or thromboses, hypertension in a third of the patients, gout, which is brought about by an increase in the production of uric acid, and, in some cases, septic ulcers. The most important laboratory finding is an increase in the values for hemoglobin, hematocrit, erythrocyte count and total erythrocyte volume, and also a neutrophilic granulocytosis or thrombocytosis in many cases. Since, on the one hand, most of the criteria are rather diffuse and, on the other hand, not all the patients fulfill these criteria, it is _ 2 _ frequently difficult to distinguish p. vera from other myeloproliferative diseases, such as chronic granulocytic leukemia or essential thrombocytosis, and thereby confirm the diagnosis. To date, the molecular cause of p. vera is completely unknown. Since, however, p. vera takes a severe course if it is not treated, accurate diagnosis is important.
An object of the invention was therefore to find the molecular cause of polycythemia rubra vera and to create the possibility of diagnosing it.
This object was achieved by isolating a gene which is expressed specifically in association with p.
vera and not in healthy control individuals. This gene is designated the PRV-1 gene (polycythemia rubra vera).
A similar nucleotide sequence is disclosed in International application WO 98/50552.
One part of the subject matter of the invention therefore relates to a polynucleotide which encodes the PRV-1 gene and essentially comprises the sequence ID
No. 1. The polynucleotides of the present invention can be single-stranded or double-stranded DNA or RNA. If they are RNA, it is then clear to the skilled person that "U" nucleotides are present in place of "T"
nucleotides. "Polynucleotide" is understood as meaning nucleic acids which contain 15 or more nucleotides.
The nucleotide sequence according to the invention is depicted in figure 1. The invention therefore relates to a polynucleotide which corresponds to the sequence shown in figure 1 and also to a polynucleotide whose nucleotide sequence exhibits minor differences. Within the meaning of the present application, minor differences are understood as meaning those sequences in which a few, preferably not more than 50 and particularly preferably not more than 25, nucleotides can be exchanged, with, however, the function of the gene encoded by the nucleotide sequence being unaffected. The skilled person is familiar with the fact that a base triplet encoding an amino acid can be replaced with another triplet which encodes the same r amino acid. In addition to this, regions which are of less importance can be deleted and/or mutated to a minor extent. In a particular embodiment, the polynucleotide comprises nucleotides 36 to 1346 of sequence No. 1, that is the coding region of the PRV-1 gene. Other embodiments comprise nucleotides 36 to 1262 or 36 to 1238 of sequence No. 1. This region presumably encodes the active region of the PRV-1 polypeptide.
Finally, the polynucleotide of the invention can also comprise nucleotides 39 to 1346, 39 to 1262 or 39 to 1238 of sequence No. 1, such that the codon which encodes the starting methionine is not present. A
preferred embodiment is a polynucleotide which comprises nucleotides 99 to 1346, 99 to 1262 or 99 to 1238 of sequence No. 1. This results in the codons at the 5' end which encode the signal peptide of the PRV-1 polypeptide not being present.
The polynucleotide according to the invention can also be a fragment of the PRV-1 gene. As a rule, the fragment possesses more than 100 nucleotides, preferably, however, more than 300 nucleotides. The fragments can also be used as primers or as probes, in particular for PCR; in this case, the fragments can be truncated to fit the purpose. Usually, primers have a length of between 10 and 30 nucleotides and probes have a length of between 15 and 50 nucleotides.
The PRV-1 gene is an endogenous gene whose expression in healthy individuals is, however, restricted to only a few organs. Normally, it is expressed in the main in the hematopoietic organs, i.e.
in bone marrow and fetal liver, and weakly expressed in the spleen, but not expressed in heart, muscle, pancreas or kidney. In patients who are suffering from p. vera, this gene is very strongly overexpressed in the hematopoietic cells, in particular.
The PRV-1 gene encodes a protein which exhibits the protein sequence shown in Figure 2. The signal peptide, which is present in the protein sequence of all surface molecules and normally removed when the protein is processed, is divided off by a hyphen. The protein has the sequence ID No. 2. Another aspect of the invention is consequently an essentially pure polypeptide having the sequence No. 2 or a polypeptide having the sequence No. 2 but lacking the signal peptide (i.e. amino acids 22 to 437 of sequence No. 2).
Other embodiments encompass amino acids 1 to 409, 22 to 409, 1 to 401 or 22 to 401 of sequence No. 2 (what is probably the active region of the protein).
With regard to biological activity, the polypeptide according to the invention is preferably glycosylated; it is most preferably N-glycosylated. It can then be glycosylated at at least one of the amino acids Asn-46, Asn-189 and Asn-382 of the PRV-1 polypeptide (the amino acid numbers refer to the sequence No. 2). The invention also encompasses fragments of the polypeptides according to the invention which are N-glycosylated. The fragments are at least 50 amino acids in length, preferably at least 100 amino acids and most preferably at least 150 amino acids. In another embodiment, a polypeptide can be O-glycosylated.
It is clear to the skilled person that particular amino acids can be replaced with other amino acids without impairing the biological activity of the protein. Such modified forms of the polypeptides according to the invention are also part of the subject matter of the invention (variants). The amino acid replacements are those which do not have a negative effect on the biological activity of the protein. The skilled person can make use of well known rules for selecting the replacements.
Depending on the method of preparation, the PRV-1 polypeptide can, for example, possess a glycosyl phosphatidylinositol anchor. This is then bonded to the amino acids which correspond to amino acids 407 to 409 in sequence ID No. 2. A GPI anchor is used to anchor a protein by means of a lipid on the outside of the cell membrane. However, for reasons which have not so far ~ - 5 -been conclusively elucidated, it is frequently observed that GPI-linked proteins are also released into the medium. This is referred to as "shedding" . To date, it has not been clarified whether this is a specific process, i.e. such proteins are cleaved from the membrane by enzymes in a controlled manner, or whether it represents a non-specific loss of the anchor. It is consequently very probable that PRV-1 is to be found both on the cell membrane and extracellularly. The secreted form, which is not membrane-bound, is probably more important for the effect of the polypeptide as a growth factor and growth inhibitor since, as a growth factor, this form is able to diffuse and reach other cells.
It is clear to the skilled person that he can influence the attachment of the protein to the cell membrane by manipulating these C-terminal amino acids.
This particularly concerns the preparation of defined DNA constructs which are intended for expressing the PRV-1 polypeptide or fragments of this polypeptide. The codons which encode these amino acids can be mutated or deleted.
The gene encodes a surface receptor of the uPAR/Ly6 family. This receptor family can transduce mitogenic signals, i.e. signals which stimulate cell division. It is therefore assumed that overexpression of the PRV-1 gene, inter alia on the bone marrow cells of p. vera patients, contributes to hyperproliferation of these cells.
It has been found that PRV-1 is not expressed on granulocytes in healthy individuals or in patients suffering from other myeloproliferative diseases, e.g.
suffering from chronic granulocytic leukemia, acute granulocytic leukemia, essential thrombocytosis or secondary erythrocytosis.
In order to be able to use the polypeptide encoded by the PRV-1 gene for analyses and detection methods, it is expediently generated from recombinant DNA, with the recombinant DNA preferably comprising the -nucleotide sequence ID No. 1 or at least the coding region of the PRV-1 gene, that is nucleotides 36 to 1346 of sequence ID No. l, or else at least nucleotides 39 to 1262 or 39 to 1238, functionally linked to a promoter. However, the recombinant DNA can also comprise only a fragment of sequence No. 1.
The invention furthermore relates to a vector which contains the recombinant DNA for the PRV-1 polypeptide, or a fragment thereof, and to a host cell which is transfected or transformed with this vector.
The host cells may be prokaryotic, for example bacteria such as E. coli. However, the polypeptides which are expressed are then not glycosylated. Preference is therefore given to eukaryotic host cells, which are able to glycosylate the expressed protein post-translationally and modify it in other ways. Examples of eukaryotic host cells are insect cells, such as Sf9 cells, for expression following infection with recombinant baculoviruses, and mammalian cells, such as 293 cells, COS cells, CHO cells and HeLa cells. These examples are not exhaustive. It is also possible to use yeast cells as host cells. It is clear to the skilled person that the glycosylation pattern can differ depending on the host cell. The biological activity of the expression product can therefore also vary.
Particular preference is given to host cells which glycosylate the expression product in such a way that the biological activity of the protein is retained.
Another aspect of the invention is a process for preparing a polypeptide according to the invention.
In this process, a DNA encoding the polypeptide according to the invention is caused to be expressed in a host cell. The culture medium or the cells is/are employed for the subsequent isolation of the polypeptide depending on whether the expressed polypeptide is secreted by the host cell into the culture medium or remains in the cell. After that, the polypeptide according to the invention is concentrated and/or purified using methods which are known in the state of the art, for example chromatographic methods.
Methods for purifying proteins are described, for example, in Scopes, R., Protein Purification:
Principles and Practice (3rd edition), Springer Verlag (1994). In one particular embodiment, the process according to the invention encompasses the step in which glycosylated polypeptide is concentrated and/or purified. This step can take place either before the polypeptide according to the invention has been essentially purified or after it has already been essentially purified. In the latter case, the glycosylated moiety of the purified polypeptide is then separated off and isolated. In the most preferred embodiment of the process, N-glycosylated polypeptide is specifically isolated. In another embodiment of the process, polypeptide is isolated which is glycosylated at at least one of the amino acids Asn-46, Asn-189 and Asn-382 of sequence No. 2.
The PRV-1 polypeptide which is isolated from granulocytes or produced recombinantly can be employed both for diagnosing polycythemia vera and for treating the disease.
One therapeutic possibility is that of "antisense therapy". This method employs an "antisense"
RNA molecule, that is an RNA which is complementary to the PRV RNA. Since the PRV-1 RNA has the sequence 5'-AAAAGCAGAAAGAGATTACCAGCC-3' (seq. ID No. 3) at its beginning, the requisite antisense RNA directed against this sequence would possess the following nucleotide sequence: 5'-GGCTGGTAATCTCTTTCTGCTTTT-3' (seq. ID No.
4). This antisense RNA is incorporated into a vector and introduced into the p. vera cells. This RNA is introduced, for example, by means of transfection, with the vector used for the transfection preferably being configured such that it is introduced specifically into the p. vera cells. Expression of the antisense RNA
results in it no longer being possible for the PRV-1 mRNA to be translated into a polypeptide. Cells which a have been treated in this way do not then form any PRV-1 protein.
The invention therefore also relates to a process for detecting p. vera which is characterized in that the PRV-1 polypeptide, or an epitope thereof, is detected and the extent of the expression is determined.
Overexpression of this receptor on mature cells outside of the bone marrow, e.g. on granulocytes, is a strong indication of the presence of the disease p.
vera. This overexpression is expediently detected by means of an immunoassay using antibodies which are directed against the PRV-1 receptor. Suitable test methods are the known immunoassay variants which make use of PRV-1 polypeptide-specific antibodies together with other labeled antibodies which can be immobilized or in solution. The labeling can be effected in a manner known per se, for example using radioactive isotopes, by means of fluorescence or luminescence, using enzymes, by means of color-forming reactions or using other groups which are suitable for the determination. These variants are known to the skilled person and do not require any more detailed explanation here. According to the invention, ELISA tests are particularly preferred.
The antibodies which are required for specifically detecting the PRV-1 receptor can likewise be prepared in a manner which is known per se. Both monoclonal and polyclonal antibodies are suitable, with preference being given to using monoclonal antibodies.
Peptides which are derived from the protein can also be used for preparing antibodies. Within the context of the present invention, success was achieved using the peptides having the sequences:
a) KVSDLPRQWTPKN (amino acids 34 to 46) (seq. ID No.
5~, and _ g _ b) SAREKRDVQPPASQH (amino acids 391 to 405) [seq. ID
No. 6] .
The polyclonal antibodies are normally produced by immunizing a suitable host (rabbit) with the PRV-1 polypeptide, where appropriate bound to an immunological support (adjuvant), and eliciting an immune response. Monoclonal antibodies can be generated in a manner known per se using the hybridoma technique.
The antibodies can be purified by means of affinity purification. The preparation and purification of antibodies are described, for example, in "Antibodies:
A Laboratory Manual" by Harlow and Lane, Cold Spring Harbor Laboratory Press.
Furthermore, such polyclonal or monoclonal antibodies which are directed against PRV-1 can also be used for treating the disease.
In another embodiment, the PRV-1 receptor can be detected using an RT-PCR method. For this, RNA is first of all isolated from the PRV-1-overexpressing cells, which are as a rule granulocytes. A reverse transcription is then performed in a manner known per se using an RT primer. The RT primer is preferably a primer which has the following nucleotide sequence (SEQ
ID No. 7):
ATTAGGTTATGAGGTCAGAGGGAGGTT.
In this way, the specific PRV-1 RNA is transformed into DNA. This DNA is then amplified in a PCR reaction in a manner known per se. The following two primers are preferably employed for the amplification cycles:
As the sense primer (SEQ ID No. 8) GCAGAAAGAGATTACCAGCCACAGACGG.
As the antisense primer (SEQ ID No. 9) GAATCGTGGGGGTAATAGAGTTAGCAGG.
The skilled person is readily able to use the disclosed sequence to find other primers which are also suitable.
Since the RNA is used as the starting material for this method, the PCR signal is only positive when the PRV-1 gene is also expressed. As explained above, this is only the case when the patient is suffering from p. vera. PRV is not expressed in granulocytes of healthy patients. Consequently, the absence of any RT-PCR signal indicates that no p. vera is present. The quantification in the RT-PCR method is preferably effected using the TaqMan~ technology. This quantification requires a probe in addition to primers.
The preferred sequence of the probe is 5'-TTCTTGTTGAACCACACCAGACAAATCGG-3' (SEQ ID N0:10~.
Quantitative RT-PCR for detecting the PRV-1 transcript is therefore also part of the subject matter of this invention.
In another alternative, it is also possible to use a blotting method, preferably a Northern Blot, for diagnosing p. vera. For such a method, the RNA is isolated from granulocytes and then examined for the expression of PRV-1 using a blotting method, for example Northern blotting. The cDNA sequence of SEQ ID
No. 1, or a segment of the sequence, can be used as the probe. Hybridization then only occurs if the granulocytes are derived from a patient suffering from p. vera since only then is there any expression on the granulocytes. The absence of hybridization indicates that the individual from whom the granulocytes are derived does not have p. vera.
It is also possible to use a fragment of the gene for the Northern blot hybridization. Such a fragment is normally more than 100 bases in length, preferably more than 300 bases in length.
Alternatively, various different fragments of the gene, ' - 11 -which can be used as probes in the Northern blot, can be prepared by digesting the gene with restriction endonucleases. If the fragments are derived from the cDNA, they are then present as double strands which have to be separated into the single strands for the hybridization. Suitable examples are the Bam HI-PstI
fragment from base pair 420 to base pair 831, or the PstI-PstI fragment from base pair 831 to base pair 1900.
PRV-1 mRNA, and consequently the expression of PRV-1, can also be detected by first of all reverse-transcribing the mRNA in an RT-PCR reaction and then amplifying the cDNA; the amplified DNA is then detected with a probe in a hybridization method.
In the case of a positive diagnosis, the disease has to be treated since it otherwise leads to death within a relatively short period of time. For this treatment, it is possible to use specific antibodies which are directed against PRV-1 and to which cytotoxic components can be bonded, where appropriate.
The invention therefore furthermore relates to a drug which, in addition to the customary excipients, comprises antibodies which are directed against the PRV-1 receptor.
Since the PRV-1 receptor is overexpressed in p.
vera, many antibodies are bound on the surface of the affected granulocytes when they come into contact with the anti-PRV-1 antibody. The binding of many antibodies to these cells stimulates the immunological cells to destroy these granulocytes. In this way, it is possible to eliminate the p. vera cells specifically.
Surprisingly, it has also been found that the PRV-1 polypeptide exhibits haematopoietic activity. The PRV-1 polypeptide is able to stimulate certain hematopoietic precursor cells to form erythroid colonies. It is particularly the N-glycosylated PRV-1 polypeptides which display this function. The polypeptides according to the invention which are preferred are therefore the N-glycosylated PRV-1 polypeptides, and fragments thereof, which display the growth factor activity.
Another aspect of the invention is therefore a drug which, in addition to a pharmaceutically tolerated excipient, comprises the PRV-1 polypeptide or a biologically active fragment thereof. The PRV-1 polypeptide is preferably glycosylated PRV-1 polypeptide and, even more preferably, N-glycosylated PRV-1 polypeptide or a biologically active fragment thereof. The invention also relates to drugs which comprise at least one polynucleotide according to the invention.
The present invention furthermore relates to the use of PRV-1 polypeptide, or a biologically active fragment thereof or a biologically active variant thereof, as a growth factor in vivo and ex vivo. The PRV-1 polypeptide, or a biologically active fragment thereof or a biologically active variant thereof, can be used for treating all pancytopenias and pancytopathies in the bone marrow and in the circulation (change in the cellular constituents of the peripheral blood and bone marrow). The polypeptides of the present invention can, for example, be used for treating anemias in the case of kidney failure, chemotherapy or whole body radiation, for treating neutropenias and thrombocytopenias during chemotherapy or whole body radiation, for the ex-vivo treatment of peripheral or bone marrow stem cells for expansion (multiplication) and retransfusion into the patients, and for treating sepsis, systemic inflammatory response syndrome (SIRS) or regional inflammatory reactions. The polypeptides of the present invention, or drugs which comprise them, can be administered in a wide variety of ways. The forms of administration comprise intravenous, intramuscular, subcutaneous, intraperitoneal, oral, transdermal and transmucosal administration.
The polynucleotides according to the invention can also be used for treating pancytopenias and pancytopathies. In this case, the aim is to express a PRV-1 polypeptide, or a functional fragment thereof, in cells of the affected patient. Gene therapy methods are first and foremost used in this connection. Cells can be isolated from the patient and transfected with a polynucleotide according to the invention (ex-vivo manipulation), after which they are then returned to the patient. It is also possible to conceive of methods in which the polynucleotides according to the invention gain access into the target cells by means of viral transfer. Expression of the inserted nucleic acids then leads to haematopoietic activity.
Surprisingly, it was also found that, at higher concentration, the PRV-1 polypeptide has an inhibitory effect on the growth of cells. Thus, it was observed, for example, that adding an increased quantity of PRV-1 protein virtually completely stops the formation of erythroid and granulocytic/monocytic colonies. This effect resembles the action of Interferon-a, which is used, inter alia, therapeutically in chronic myeloid leukemia (CML) and in p. vera. An endogenous inhibitory substance possesses great advantages as compared with a chemical cytostatic agent, such as hydroxyurea, which was used when Interferon-a was not yet available and is to some extent still used. A disadvantage of Interferon-a is that this active compound has very severe side effects. The patients feel as if they were suffering from a serious influenza. The present invention makes available a hematopoiesis-inhibiting substance, with the inhibitory activity being concentration-dependent.
Another aspect of the invention is therefore the use of a PRV-1 polypeptide, as described in this application, for inhibiting the growth of cells, in particular its use as a cytostatic agent. Preference is given to the polypeptide being used for inhibiting the growth of hematopoietic cells. The invention also relates to the use of a polypeptide according to the invention for producing a drug for treating proliferative diseases. These diseases are, in particular, the myeloproliferative diseases, p. vera, essential thrombocythernia, myelofibrosis, CML and also all leukemias and lymphomas and also solid tumors.
Another aspect of the invention is the use of a polynucleotide, as described in this application, of a biologically active fragment or of a biologically active variant thereof, for inhibiting the growth of cells. The polynucleotide can be incorporated into a suitable vector and transfected into suitable target cells. After the PRV-1 polypeptide, or a biologically active fragment thereof, or a biologically active variant thereof, has been expressed in an appropriate concentration, the growth-inhibiting effect comes into operation. In the same way, the polynucleotide can be incorporated into a viral vector, after which appropriate target cells are infected virally, leading to PRV-1 being expressed. The invention also relates to the use of a polynucleotide of this application for producing a drug for treating proliferative diseases, such as the myeloproliferative diseases, p. vera, essential thrombocythemia, myelofibrosis, CML and also all leukemias and lymphomas and also solid tumors.
The invention also relates to kits for detecting either polycythemia vera or disturbances of the hematopoietic system. These kits comprise a polynucleotide according to the invention and/or a polypeptide according to the invention and/or one or more antibodies according to the invention. In addition to this, the kit can also comprise a container or compositions which are suitable for implementing detection reactions. Examples of such compositions are buffer solutions, reagents for blocking membranes, hybridization solutions, secondary antibodies, substrate solutions for detection reactions, etc. The kit is preferably used for implementing PCR reactions, RT-PCR, Northern blots, Southern blots, Western blots and ELISA, RIA or similar reactions.
The following examples are given in explanation.
Example 1 Characterizing the PRV gene The following experiments were carried out in order to characterize the gene:
- the following protocol was used to isolate granulocytes from stored blood or from blood obtained by bleeding p. vera patients:
- an equal volume of 3~ dextran solution in 0.9~
NaCl was added to the blood and the mixture was left to stand at room temperature (RT) for 20 minutes.
- The mixture separated into two phases. The upper, light-colored phase was removed and centrifuged for 10 minutes at 1800 g and at RT.
- The supernatant was discarded and the cell pellet was resuspended in the same volume of 0.9~ NaCl.
- In each case 35 ml of the cells in NaCl were layered on 15 ml of Ficoll-Hypaque.
- The cells on the Ficoll-Hypaque were then centrifuged for 60 minutes at 1800 g and at RT without using the brake.
- A cell pellet and two layers with an interphase were formed.
- The layers and interphase were aspirated off and the cell pellet was resuspended for 30 seconds in 10 ml of ice-cold 0.2~ NaCl, and 10 ml of ice-cold 1.6g NaCl were added immediately after 30 seconds.
- The cells were centrifuged down for 10 minutes at 1800 g and at RT.
- They were then washed once in 10 ml of PBS and centrifuged down.
- The cell pellet contained 95-99~-pure granulocytes.
- RNA was isolated from these cells using standard methods.
- 10 mg of this RNA were examined for the expression of PRV-1 in a Northern blot. The entire cDNA
sequence shown in SEQ ID No. 1 was used as a probe.
This experiment was performed on 39 p. vera patients and 29 control samples of stored blood. The PRV-1 probe was found to hybridize strongly in the case of the p. vera patients. No hybridization was observed in healthy control samples.
Example 2 PRV-1 possesses growth factor activity Embryos were removed from a pregnant mouse 13.5 days after fertilization. The fetal livers were removed. The cells contained in them were stained using antibodies and enriched for particular cells, and depleted for other cell types, by means of column chromatography. This results in a cell mixture which is enriched for certain hematopoietic precursor cells (colony forming units-erythroid, CFU-E). Thus, while in all approximately 2~ of the fetal liver consists of CFU-E, 30-40~ of the enriched cells consist of CFU-E.
These CFU-Es were transfected using a retrovirus. To do this, a packaging cell line, designated 293-T, was itself transfected 48 hours previously. 293-T cells are an established human embryonic kidney cell line. 293-T cells are stably transfected with several genes from a retrovirus. If these 293-T cells are now transfected with two plasmids, termed pOS and pKAT, the 293-T cells then produce ~a retrovirus which is able to infect murine fetal liver cells. If the 293-T cells are transfected with an empty pOS vector and pKAT, a wild-type retrovirus, which only expresses retroviral proteins, is then produced. On the other hand, cloning a human gene, e.g. PRV-1, into the pOS vector results in the production of a retrovirus which expresses this protein _ 1~ -when it has infected cells. The 293-T cells secrete the retrovirus into the cell culture medium.
After two days, the cell culture medium from the transfected 293-T cells which contains the retrovirus is harvested and filtered once through a 0.45 um filter. In order to transfect the fetal liver cells, these latter cells are mixed with the filtered cell culture medium, which contains the retrovirus, and centrifuged for 2 hours at 1800 rpm and 20°C in the added presence of Polybren. The transfected fetal liver cells were then cultured in a medium (Methocult, from Cell Systems) which contains, in addition to the usual salts and amino acids, fetal calf serum, 0.0001-0.4 IU
of erythropoeitin (EPO)/ml and methyl cellulose (0.8~).
The CFU-Es require EPO in order to form hematopoietic colonies. The methyl cellulose solidifies the medium in the form of a jelly, thereby fixing individual cells in this jelly so that, in contrast to being in a liquid medium, they cannot move. It is therefore possible to observe whether a hematopoietic colony is or is not formed from a single cell. CFU-Es form erythroid colonies, that is colonies which contain red blood cells and their precursor cells.
After three days, a count is taken of the number of hematopoietic colonies which have developed.
Various mixtures are compared. The mixtures were not all examined in each experiment; mixtures 1-3 are very similar controls and each of them can be compared individually with mixture 4.
Mixture 1: Cells which were not transfected with a retrovirus;
Mixture 2: Cells which were transfected with an empty pOS vector;
Mixture 3: Cells which were transfected with a "green fluorescent protein" (GFP), a protein which is not hematopoietically active.
Mixture 4: Cells which were transfected with pOS-PRV-1 (vector + gene according to the invention).
Table 1: The table lists the results obtained from three experiments which were performed as described. The figures in each case indicate the number of colonies.
Mixture 1 Mixture 2 Mixture Mixture 4 un- empty vector GFP PRV-1 transfected (pOS) (pOS-GFP) (pOS-PRV-1) Experiment 116 156 80 326 Experiment 271 273 410 Experiment 120 131 291 The experiments demonstrate that CFU-Es which were transfected with PRV-1 form very many more colonies (up to three times as many) than do the various control CFU-Es. This result indicates that PRV-1 is a growth factor for CFU-E.
Example 3 Solubility of the PRV-1 growth factor A further experiment was carried out in order to investigate whether PRV-1 is a soluble growth factor or whether cell-cell contact is required. It is not only a retrovirus which is produced by the packaging cell line 293-T after it has been transfected with the pOS and pKAT vectors. In addition, the 293-T cells also synthesize the protein encoded by the gene cloned in pOS, i.e. PRV-1 in the present case. If the gene product is a soluble protein, it is secreted into the medium which surrounds the packaging cell line 293-T.
If the 293-T cells are transfected only with the pOS
vector, without pKAT, no retroviruses are then formed.
The cell culture medium then only contains the soluble protein produced by the cells. Medium which is derived from pOS-PRV-1-transfected cells, and which does not contain any retrovirus, is mixed with CFU-Es and the whole is plated out in the methyl cellulose medium; the resulting colonies are then counted.
The following results were obtained:
Table 2: Solubility of PRV-1. The figures in each case indicate the number of colonies.
Mixture 1 Mixture 2 Mixture Mixture 4 un- empty vector GFP PRV-1 transfected (pOS) (pOS-GFP) (pOS-PRV-1) Experiment 137 187 557 In this experiment, too, CFU-Es which were treated with PRV-1-containing medium formed very many more hematopoietic colonies than did control cells. It can be concluded from this result that PRV-1 is a soluble growth factor.
Example 4 PRV-1 also has an inhibitory, cytostatic effect.
The experiments were carried out on peripheral blood cells. Since a small number of precursor cells are also circulating in the peripheral blood in healthy individuals, it is possible to culture hematopoietic colonies from peripheral blood cells in a suitable medium (methyl cellulose). 40 ml of peripheral venous blood were withdrawn from a healthy donor (while initially introducing heparin or EDTA as an anticoagulant). 15 ml of Ficoll/Hypaque were added to the blood and the mixture was centrifuged at 1 600 rpm for 40 minutes without braking. This results in the production of a density gradient which fractionates the blood into its cellular constituents. After the centrifugation, what are termed the mononuclear cells, which also include the stem cells, are to be found at the interphase between serum and Ficoll. This interphase was removed and washed in PBS (isotonic salt solution). This yields purified mononuclear cells, approximately 0.1~ of which are hematopoietic stem cells.
The mononuclear cells were taken up in a particularly rich medium (IMDM) which contained an added concentration of 3$ FCS (fetal calf serum) . This 3~ FCS/IMDM subsequently contained the modifications, i.e. PRV-1 was or was not added to it.
The mononuclear cells in IMDM were added, at a density of 7 x 105 cells/ml, to a commercially available medium supplied by Stem Cell Technologies (Methocult), which contained IMDM and 30$ FCS, 1~ BSA (bovine serum albumin), mercaptoethanol, 2 mM L-glutamine, 3 IU EPO
(erythropoietin)/ml and 1.0~ methyl cellulose. The cells grew for 14 days in this medium. The few stem cells which are present in this mixture are able to develop into hematopoietic colonies. Usually, between 100 and 200 hematopoietic colonies develop for every 7 x 105 cells employed.
A cell line which expresses a very high quantity of PRV-1 was also constructed. The PRV-1 which is produced by these cells is altered such that it no longer possesses a lipid anchor. The expression product consists of the amino acids 1-401 of the sequence SEQ ID No:2; the amino acids 402-437 are therefore missing. This altered PRV-1 is therefore not, like wild-type PRV-1, incorporated into the cell membrane by means of a lipid anchor, but is instead completely secreted from the cells. As in example 3, the cell line consisted of 293 cells which do not produce any retrovirus but which express protein (PRV-1).
For the hematopoietic colony assays, the mononuclear blood cells were now taken up either in IMDM medium, which had been incubated for 48 hours with untransfected cells (293), or in medium which had been incubated for 48 hours with cells which were expressing the altered PRV-1 (293-GPI-less-PRV-1). The ability of these cells to form hematopoietic colonies was then investigated. The number of erythroid (red) and myeloid (white) blood cell colonies was determined after 14 days. The experiment was repeated three times and also carried out on different days and using different blood donors. Duplicates were also evaluated within the experiment. The following results were obtained:
Experiment 1 Cell Donor 1 Donor 2 supernatant Red White Red White colonies colonies colonies colonies 293-GPI-less- 7/3 0/0 31/19 0/0 Experiment 2 Cell Donor 1 Donor 2 supernatant Red White Red White colonies colonies colonies colonies 293-GPI-less- 0/0 0/0 0/0 0/0 Experiment 3 Cell Donor 1 Donor 2 supernatant Red White Red White colonies colonies colonies colonies s 293-GPI-less- 4/3 0/6 0/1 3/0 It can be concluded from this data that a higher dose of PRV-1 than that used in example 3 possesses a cytostatic effect.
Example 5 The growth factor PRV-1 is N-glycosylated Granulocytes were isolated from a patient suffering from p. vera, and protein extracts were prepared from these cells using a standard protocol.
These protein extracts were treated in accordance with the protocol for the "N-Glycosidase F Deglycosylation Kit" supplied by Boehringer Mannheim. In detail, this means that a "denaturation buffer" was added to the protein extracts and the mixtures were heated at 95°C
for 3 minutes, after which they were treated either with "reaction buffer" or with "reaction buffer" plus N-glycosidase. Each mixture was incubated overnight at 37°C and the proteins were analyzed on a PAGE gel electrophoresis followed by a Western blot. The PRV-1 protein was detected with an antibody directed against a protein having the amino acid sequence ID No. 5. The results show that while PRV-1 protein purified from granulocytes is 60-65 kDa in size, it is only 40 kDa in size after having been digested with N-glycosidase.
This clearly proves that PRV-1 is glycosylated on asparagine residues (asparagine = N).
SEQUEPICE LISTII~IG
<110> Universitatsklinikum Freiburg <120> THE PRV-1 GENE AiID USE THEREOF
<130> E980930 <140> PCT/EP00/09594 <141> 2000-09-29 <150> DE 199 47 010.3 <151> 1999-09-30 <160> 10 <170> PADAT Sequenzmodul, Version I.0 <210> 1 <211> 1600 <212> DNA
<213> homo Sapiens <220>
<223>
<400> 1 aaaagcagaaagagattaccagccacagacgggtcatgagcgcggtattactgctggcc= 60 tcctggggttcatcctcccactgccaggagtgcaggcgctgctctgccagtttgggacag 120 ttcagcatgtgtggaaggtgtccgacctgccccggcaatggacccctaagaa~~accagct180 gcgacagcggcttggggtgccaggacacgttgatgctcattgagagcggaccccaagtga 240 gcctggtgctctccaagggctgcacggaggccaaggaccaggagccccgcgtcactgagc 300 accggatgggccccggcctctccctgatctcctacaccttcgtgtgccgccaggaggact 360 tctgcaacaacctcgttaactccctcccgctttgggccccacagcccccagcagacccaa 420 gatccttgaggtgcccagtctgcttgtctatggaaggctgtctggaggggacaacagaag 480 agatctgccccaaggggaccacacactgttatgatggcctcctcaggctcaggggaggag 540 gcatcttctccaatctgagagtccagggatgcatgccccagccaggttgcaacctgctca 600 atgggacacaggaaattgggcccgtgggtatgactgagaactgcaataggaaagatttt= 660 tgacctgtcatcgggggaccaccattatgacacacggaaacttggctcaagaacccactg 720 attggaccacatcgaataccgagatgtgcgaggtggggcaggtgtgtcaggagacgctg= 780 tgctcatagatgtaggactcacatcaaccctggtggggacaaaaggctgcagcactgttg 840 gggctcaaaattcccagaagaccaccatccactcagcccctcctggggtgcttgtggcct 900 cctatacccacttctgctcctcggacctgtgcaatagtgccagcagcagcagcgttctgc 960 tgaactccctccctcctcaagctgcccctgtcccaggagaccggcagtgtcctacctgtg 1020 tgcagccccttggaacctgttcaagtggctccccccgaatgacctgccccaggggcgcca 100 ctcattgttatgatgggtacattcatctctcaggaggtgggctgtccaccaaaatgagca 1140 ttcagggctgcgtggcccaaccttccagcttcttgttgaaccacaccagacaaatcggg~ 1200 tcttctctgcgcgtgagaagcgtgatgtgcagcctcctgcctctcagcatgagggaggtg 1260 gggctgagggcctggagtctctcacttggggggtggggctggcactggccccagcgctgt 1320 ggtggggagtggtttgcccttcctgctaactctattacccccacgattcttcaccgctgc 1380 tgaccacccacactcaacctccctctgacctcataacctaatggccttggacaccagatt 1~d0 ctttcccattctgtccatgaatcatcttccccacacacaatcattcatatctactcacct 1500 aacagcaacactggggagagcctggagcatccggacttgccctatgggagaggggacgct 1560 ggaggagtggctgcatgtatctgataatacagaccctgtc 1600 <210>
<211>
<212>
PRT
<213> Sapiens homo <400> 2 Met Ser Ala Val Leu Leu Leu Ala Leu Leu Gly Phe Ile Leu Pro Leu Pro Gly Val Gln Ala Leu Leu Cys Gln Phe Gly Thr Val Gln His 'Jal Trp Lys Val Ser Asp Leu Pro Arg Gln Trp Thr Pro Lys Asn Thr Ser Cys Asp Ser Gly Leu Gly Cys Gln Asp Thr Leu Met Leu Ile Glu Ser Gly Pro Gln Val Ser Leu Val Leu Ser Lys Gly Cys Thr Glu Ala Lys Asp Gln Glu Pro Arg Val Thr Glu His Arg Met Gly Pro Gly Leu Ser Leu Ile Ser Tyr Thr Phe Val Cys Arg Gln Glu Asp Phe Cys Asn Asn Leu Val Asn Ser Leu Pro Leu Trp Ala Pro Gln Pro Pro Ala Asp Pro Gly Ser Leu Arg Cys Pro Val Cys Leu Ser Met Glu Gly Cys Lsu Glu Gly Thr Thr Glu Glu Ile Cys Pro Lys Gly Thr Thr His Cys Tyr Asp Gly Leu Leu Arg Leu Arg Gly Gly Gly Ile Phe Ser Asn Leu Arg Val Gln Gly Cys Met Pro Gln Pro Gl,v Cys Asn Leu Leu Asn Gly Thr Gln Glu Ile Gly Pro Val Gly Met Thr Glu Asn Cys Asn Arg Lys Asp Phe Leu Thr Cys His Arg Gly Thr Thr Ile hfet Thr His Gly Asn Leu Ala Gln Glu Pro Thr Asp Trp Thr Thr Ser Asn Thr Glu Met Cys Glu Val Gly Gln Val Cys Gln Glu Thr Leu Leu Leu Ile Asp Val Gly L?u Thr Ser Thr Leu Val Gly Thr Lys Gly Cys Ser Thr Val Gly Ala Gln Asn Ser Gln Lys Thr Thr Ile His Ser Ala Pro Pro Gly Val Leu Val Ala Ser Tyr Thr His Phe Cys Ser Ser Asp Leu Cys Asn Ser Ala Ser Ser Ser Ser Val Leu Leu Asn Ser Leu Pro Pro Gln Ala Ala Pro ~.'al Pro Gly Asp Arg Gln Cys Pro Thr Cys Val Gln Pro Leu Gly Thr Cls Ser Ser Gly Ser Pro Arg Met Thr Cys Pro Arg Gly Ala Thr His Cls Tyr Asp Gly Tyr Ile His Leu Ser G1,; Gly Gly Leu Ser Thr Lys ffet Ser Ile Gln Gly Cys Val Ala Gln Pro Ser Ser Phe Leu Leu Asn His Thr Arg Gln Ile Gly Ile Phe Ser Ala Arg Glu Lys Arg Asp Val Gln Pro Pro Ala Ser Gln His Glu Gly Gly Gly Ala Glu Gly Leu Glu Ser Leu Thr Trp Gly Val Gly Leu Ala Leu Ala Pro Ala Leu Trp Trp Gljr Val Val Cys Pro Ser Cys <210> 3 <211> 24 <212> RNA
<213> Artificial Sequence <220>
<223> 5'-end of PRV-1-sequence <400> 3 aaaagcagaa agagattacc agcc 24 <210> 4 <211> 24 <212> RNA
<213> Artificial Sequence <220>
<223> Antisense-Molecule <400> 4 ggctggtaat ctctttctgc tttt 2:~
<210> 5 <211> 13 <212> PRT
<213> Artificial Sequence <220>
<223> amino acids 34-46 of PRV-1 <900> 5 Lys Val Ser Asp Leu Pro Arg Gln Trp Thr Pro Lys Asn <210> 6 <211> 15 <212> PRT
<213> Artificial Sequence <220>
<223> amino acids 391-405 of PRV-1 <400> 6 Ser Ala Arg Glu Lys Arg Asp Val Gln Pro Pro Ala Ser Gln His <210> 7 <211> 27 <212> DNA
<213> Artificial Sequence <220>
<223> RT-Primer <400> 7 attaggttat gaggtcagag ggaggtt 27 <210> a <211> 28 <212> DNA
<213> Artificial Sequence <220>
<223> sense-Primer <400> 8 gcagaaagag attaccagcc acagacgg 2~
<210> 9 <211> 28 <212> DDTA
<213> Artificial Sequence <220>
<223> antisense-Primer <400> 9 gaatcgtggg ggtaatagag ttagcagg <210> 10 <211> 29 <212> DNA
<213> Artificial Sequence <220>
<223> probe <400> 10 ttcttgttga accacaccag acaaatcgg 29
Claims (11)
1. The use of an N-glycosylated polypeptide which essentially comprises one of the following amino acid sequences:
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
amino acids 22-401 of sequence No. 2;
or of a fragment thereof containing at least 50 amino acids or of a polypeptide which essentially comprises one of the following amino acid sequences:
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
amino acids 22-401 of sequence No. 2;
or of a biologically active fragment thereof or a biologically active variant thereof, for producing a drug which acts as a growth factor.
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
amino acids 22-401 of sequence No. 2;
or of a fragment thereof containing at least 50 amino acids or of a polypeptide which essentially comprises one of the following amino acid sequences:
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
amino acids 22-401 of sequence No. 2;
or of a biologically active fragment thereof or a biologically active variant thereof, for producing a drug which acts as a growth factor.
2. The use of an N-glycosylated polypeptide which essentially comprises one of the following amino acid sequences:
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
amino acids 22-401 of sequence No. 2;
or of a fragment thereof containing at least 50 amino acids or of a polypeptide which essentially comprises one of the following amino acid sequences:
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
or of a biologically active fragment thereof or a biologically active variant thereof, for producing a drug for treating pancytopenias and pancytophathies in the bone marrow and in the circulation.
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
amino acids 22-401 of sequence No. 2;
or of a fragment thereof containing at least 50 amino acids or of a polypeptide which essentially comprises one of the following amino acid sequences:
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
or of a biologically active fragment thereof or a biologically active variant thereof, for producing a drug for treating pancytopenias and pancytophathies in the bone marrow and in the circulation.
3. The use of a polynucleotide which essentially comprises one of the following nucleotide sequences:
nucleotides 1-1600 of sequence No. 1;
nucleotides 36-1346 of sequence No. 1;
nucleotides 36-1262 of sequence No. 1;
nucleotides 36-1238 of sequence No. 1;
nucleotides 39-1346 of sequence No. l;
nucleotides 39-1262 of sequence No. 1;
nucleotides 39-1238 of sequence No. 1;
nucleotides 99-1346 of sequence No. 1;
nucleotides 99-1262 of sequence No. 1;
nucleotides 99-1238 of sequence No. 1;
or of a fragment thereof or a variant thereof, for producing a drug for treating pancytopenias and pancytopathies in the bone marrow and in the circulation.
nucleotides 1-1600 of sequence No. 1;
nucleotides 36-1346 of sequence No. 1;
nucleotides 36-1262 of sequence No. 1;
nucleotides 36-1238 of sequence No. 1;
nucleotides 39-1346 of sequence No. l;
nucleotides 39-1262 of sequence No. 1;
nucleotides 39-1238 of sequence No. 1;
nucleotides 99-1346 of sequence No. 1;
nucleotides 99-1262 of sequence No. 1;
nucleotides 99-1238 of sequence No. 1;
or of a fragment thereof or a variant thereof, for producing a drug for treating pancytopenias and pancytopathies in the bone marrow and in the circulation.
4. The use of an N-glycosylated polypeptide which essentially comprises one of the following amino acid sequences:
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
amino acids 22-401 of sequence No. 2;
or of a fragment thereof containing at least 50 amino acids or of a polypeptide which essentially comprises one of the following amino acid sequences:
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
amino acids 22-401 of sequence No. 2;
or of a biologically active fragment thereof or a biologically active variant thereof, for producing a drug for treating and/or multiplying endogenous cells and/or established cell lines ex vivo or in vitro.
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
amino acids 22-401 of sequence No. 2;
or of a fragment thereof containing at least 50 amino acids or of a polypeptide which essentially comprises one of the following amino acid sequences:
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
amino acids 22-401 of sequence No. 2;
or of a biologically active fragment thereof or a biologically active variant thereof, for producing a drug for treating and/or multiplying endogenous cells and/or established cell lines ex vivo or in vitro.
5. The use of an N-glycosylated polypeptide which essentially comprises one of the following amino acid sequences:
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
amino acids 22-401 of sequence No. 2;
or of a fragment thereof containing at least 50 amino acids or of a polypeptide which essentially comprises one of the following amino acid sequences:
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
amino acids 22-401 of sequence No. 2;
or of a biologically active fragment thereof or a biologically active variant thereof, for producing a drug for inhibiting the growth of cells.
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
amino acids 22-401 of sequence No. 2;
or of a fragment thereof containing at least 50 amino acids or of a polypeptide which essentially comprises one of the following amino acid sequences:
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
amino acids 22-401 of sequence No. 2;
or of a biologically active fragment thereof or a biologically active variant thereof, for producing a drug for inhibiting the growth of cells.
6. The use as claimed in claim 5, characterized in that the polypeptide is used as a cytostatic agent.
7. The use of an N-glycosylated polypeptide which essentially comprises one of the following amino acid sequences:
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
amino acids 22-401 of sequence No. 2;
or of a fragment thereof containing at least 50 amino acids or of a polypeptide which essentially comprises one of the following amino acid sequences:
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
amino acids 22-401 of sequence No. 2;
or of a biologically active fragment thereof or a biologically active variant thereof, for producing a drug for treating proliferative diseases.
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
amino acids 22-401 of sequence No. 2;
or of a fragment thereof containing at least 50 amino acids or of a polypeptide which essentially comprises one of the following amino acid sequences:
amino acids 1-437 of sequence No. 2;
amino acids 1-409 of sequence No. 2;
amino acids 1-401 of sequence No. 2;
amino acids 22-437 of sequence No. 2;
amino acids 22-409 of sequence No. 2;
amino acids 22-401 of sequence No. 2;
or of a biologically active fragment thereof or a biologically active variant thereof, for producing a drug for treating proliferative diseases.
8. The use as claimed in claim 7, characterized in that the proliferative disease is selected from the group comprising myeloproliferative diseases, p. vera, essential thrombocythemia, myelofibrosis, CML, all leukemias and lymphomas and also solid tumors.
9. The use of a polynucleotide which essentially comprises one of the following nucleotide sequences:
nucleotides 1-1600 of sequence No. 1;
nucleotides 36-1346 of sequence No. 1;
nucleotides 36-1262 of sequence No. 1;
nucleotides 36-1238 of sequence No. 1;
nucleotides 39-1346 of sequence No. 1;
nucleotides 39-1262 of sequence No. 1;
nucleotides 39-1238 of sequence No. 1;
nucleotides 99-1346 of sequence No. 1;
nucleotides 99-1262 of sequence No. 1;
nucleotides 99-1238 of sequence No. 1;
or of a fragment thereof or a variant thereof, for inhibiting the growth of cells.
nucleotides 1-1600 of sequence No. 1;
nucleotides 36-1346 of sequence No. 1;
nucleotides 36-1262 of sequence No. 1;
nucleotides 36-1238 of sequence No. 1;
nucleotides 39-1346 of sequence No. 1;
nucleotides 39-1262 of sequence No. 1;
nucleotides 39-1238 of sequence No. 1;
nucleotides 99-1346 of sequence No. 1;
nucleotides 99-1262 of sequence No. 1;
nucleotides 99-1238 of sequence No. 1;
or of a fragment thereof or a variant thereof, for inhibiting the growth of cells.
10. The use of a polynucleotide which essentially comprises one of the following nucleotide sequences:
nucleotides 1-1600 of sequence No. 1;
nucleotides 36-1346 of sequence No. 1;
nucleotides 36-1262 of sequence No. 1;
nucleotides 36-1238 of sequence No. 1;
nucleotides 39-1346 of sequence No. 1;
nucleotides 39-1262 of sequence No. 1;
nucleotides 39-1238 of sequence No. 1;
nucleotides 99-1346 of sequence No. 1;
nucleotides 99-1262 of sequence No. 1;
nucleotides 99-1238 of sequence No. 1;
or of a fragment thereof or a variant thereof, for producing a drug for treating proliferative diseases.
nucleotides 1-1600 of sequence No. 1;
nucleotides 36-1346 of sequence No. 1;
nucleotides 36-1262 of sequence No. 1;
nucleotides 36-1238 of sequence No. 1;
nucleotides 39-1346 of sequence No. 1;
nucleotides 39-1262 of sequence No. 1;
nucleotides 39-1238 of sequence No. 1;
nucleotides 99-1346 of sequence No. 1;
nucleotides 99-1262 of sequence No. 1;
nucleotides 99-1238 of sequence No. 1;
or of a fragment thereof or a variant thereof, for producing a drug for treating proliferative diseases.
11. The use as claimed in claim 10, characterized in that the proliferative disease is selected from the group comprising myeloproliferative diseases, p. vera, essential thrombocythemia, myelofibrosis, CML, all leukemias and lymphomas and also solid tumors.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19947010A DE19947010A1 (en) | 1999-09-30 | 1999-09-30 | The PRV-1 gene and its use |
| DE19947010.3 | 1999-09-30 | ||
| PCT/EP2000/009594 WO2001023554A1 (en) | 1999-09-30 | 2000-09-29 | The prv-1 gene and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2387702A1 true CA2387702A1 (en) | 2001-04-05 |
Family
ID=7923937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002387702A Abandoned CA2387702A1 (en) | 1999-09-30 | 2000-09-29 | The prv-1 gene and use thereof |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1220920A1 (en) |
| JP (1) | JP2003510077A (en) |
| KR (1) | KR20020047191A (en) |
| CN (1) | CN1377408A (en) |
| AU (1) | AU1132401A (en) |
| BG (1) | BG106554A (en) |
| BR (1) | BR0014444A (en) |
| CA (1) | CA2387702A1 (en) |
| CZ (1) | CZ20021094A3 (en) |
| DE (1) | DE19947010A1 (en) |
| EA (1) | EA200200286A1 (en) |
| EE (1) | EE200200168A (en) |
| HR (1) | HRP20020269A2 (en) |
| HU (1) | HUP0203080A2 (en) |
| IL (1) | IL148770A0 (en) |
| MX (1) | MXPA02002800A (en) |
| NO (1) | NO20021498L (en) |
| PL (1) | PL354184A1 (en) |
| SK (1) | SK4262002A3 (en) |
| WO (1) | WO2001023554A1 (en) |
| ZA (1) | ZA200202379B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL158599A0 (en) * | 2003-10-26 | 2004-05-12 | Yeda Res & Dev | Methods of modulating hematopoiesis |
| KR102115438B1 (en) | 2012-05-21 | 2020-05-27 | 제넨테크, 인크. | Methods for improving safety of blood-brain barrier transport |
| EP3638774A1 (en) * | 2017-06-14 | 2020-04-22 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001515361A (en) * | 1997-05-06 | 2001-09-18 | ザイモジェネティクス，インコーポレイティド | Novel tumor antigen |
| IL139686A0 (en) * | 1998-06-02 | 2002-02-10 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| DE19849044A1 (en) * | 1998-10-23 | 2000-04-27 | Univ Ludwigs Albert | New polycythemia rubra vera-related polypeptide useful for diagnosis and for developing therapeutic antibodies |
| AU777006B2 (en) * | 1998-12-16 | 2004-09-30 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
-
1999
- 1999-09-30 DE DE19947010A patent/DE19947010A1/en not_active Withdrawn
-
2000
- 2000-09-29 KR KR1020027004095A patent/KR20020047191A/en not_active Application Discontinuation
- 2000-09-29 EA EA200200286A patent/EA200200286A1/en unknown
- 2000-09-29 EE EEP200200168A patent/EE200200168A/en unknown
- 2000-09-29 CA CA002387702A patent/CA2387702A1/en not_active Abandoned
- 2000-09-29 MX MXPA02002800A patent/MXPA02002800A/en unknown
- 2000-09-29 CZ CZ20021094A patent/CZ20021094A3/en unknown
- 2000-09-29 PL PL00354184A patent/PL354184A1/en not_active IP Right Cessation
- 2000-09-29 WO PCT/EP2000/009594 patent/WO2001023554A1/en not_active Application Discontinuation
- 2000-09-29 SK SK426-2002A patent/SK4262002A3/en unknown
- 2000-09-29 CN CN00813580A patent/CN1377408A/en active Pending
- 2000-09-29 HU HU0203080A patent/HUP0203080A2/en unknown
- 2000-09-29 AU AU11324/01A patent/AU1132401A/en not_active Abandoned
- 2000-09-29 JP JP2001526936A patent/JP2003510077A/en active Pending
- 2000-09-29 BR BR0014444-4A patent/BR0014444A/en not_active Application Discontinuation
- 2000-09-29 EP EP00972665A patent/EP1220920A1/en not_active Withdrawn
- 2000-09-29 IL IL14877000A patent/IL148770A0/en unknown
-
2002
- 2002-03-25 ZA ZA200202379A patent/ZA200202379B/en unknown
- 2002-03-26 NO NO20021498A patent/NO20021498L/en not_active Application Discontinuation
- 2002-03-27 BG BG106554A patent/BG106554A/en unknown
- 2002-03-28 HR HR20020269A patent/HRP20020269A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003510077A (en) | 2003-03-18 |
| ZA200202379B (en) | 2003-10-29 |
| EE200200168A (en) | 2003-04-15 |
| BG106554A (en) | 2003-01-31 |
| PL354184A1 (en) | 2003-12-29 |
| EP1220920A1 (en) | 2002-07-10 |
| HUP0203080A2 (en) | 2002-12-28 |
| CN1377408A (en) | 2002-10-30 |
| NO20021498L (en) | 2002-05-23 |
| DE19947010A1 (en) | 2001-04-05 |
| WO2001023554A1 (en) | 2001-04-05 |
| SK4262002A3 (en) | 2002-09-10 |
| NO20021498D0 (en) | 2002-03-26 |
| AU1132401A (en) | 2001-04-30 |
| BR0014444A (en) | 2002-06-11 |
| MXPA02002800A (en) | 2002-07-22 |
| EA200200286A1 (en) | 2002-12-26 |
| KR20020047191A (en) | 2002-06-21 |
| CZ20021094A3 (en) | 2002-06-12 |
| IL148770A0 (en) | 2002-09-12 |
| HRP20020269A2 (en) | 2003-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kato et al. | Purification and characterization of thrombopoietin | |
| US7122654B2 (en) | Vascular endothelial growth factor D (VEGF-D) antibodies and vectors, and methods of use | |
| JP2002516103A (en) | Interleukin 21 and interleukin 22 | |
| JP2001524814A (en) | 28 human secreted proteins | |
| JPH07107983A (en) | Adjustment of jak kinase and cytokinin signal transduction | |
| JP2001522239A (en) | 87 human secreted proteins | |
| JP2002518010A (en) | 94 human secreted proteins | |
| JPH07505139A (en) | liver growth factor receptor | |
| JP2002533058A (en) | 97 human secreted proteins | |
| JP2001521383A (en) | 20 human secretory proteins | |
| US5858701A (en) | DNA encoding an insulin receptor substrate | |
| JP2002512521A (en) | 32 human secreted proteins | |
| US6686153B1 (en) | PRV-1 gene and the use thereof | |
| CA2387702A1 (en) | The prv-1 gene and use thereof | |
| KR20030096447A (en) | Short forms of chemokine beta-8 | |
| KR20010043090A (en) | NOVEL POLYPEPTIDE, cDNA ENCODING THE SAME AND UTILIZATION THEREOF | |
| JP2002502601A (en) | Dendritic enriched secretory lymphocyte activating molecule | |
| JP2002509693A (en) | Cadherin-derived growth factor and uses thereof | |
| 이현채 | The Role of Adenylyl Cyclase-Associated Protein1 (CAP1) in Transendothelial Migration of Monocytes to Promote Chronic Inflammation | |
| JP2002510192A (en) | 186 human secreted proteins | |
| CA2233367A1 (en) | Short forms of chemokine .beta.-8 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDC | Discontinued application reinstated | ||
| FZDE | Discontinued |